<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914251</url>
  </required_header>
  <id_info>
    <org_study_id>073/09</org_study_id>
    <nct_id>NCT00914251</nct_id>
  </id_info>
  <brief_title>Vascular Effects of Hesperidin in Metabolic Syndrome</brief_title>
  <official_title>Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <brief_summary>
    <textblock>
      It has been suggested that cardiovascular risk factors either independently or in cluster
      (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular
      diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity
      and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator
      actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be
      explored, no data on in vivo vascular effect of this flavanone has been ever acquired.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of oral supplementation of hesperidin</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Hesperidin, 500 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg daily of oral Hesperidin for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hesperidin</intervention_name>
    <description>Administration of oral Hesperidin, 500 mg/daily</description>
    <arm_group_label>Hesperidin, 500 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of oral Placebo, 500 mg/daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic Syndrome (ATPIII criteria)

          -  BMI &lt;35

          -  Age 20-55

        Exclusion Criteria:

          -  History of cancer.

          -  History of cardiovascular diseases.

          -  Any other acute or chronic illness which requires administration of steroids or other
             drugs able to interfere with glucose or lipid metabolism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rome Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Rizza, MD</last_name>
      <email>rizza@med.uniroma2.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Rizza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manfredi Tesauro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davide Lauro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Muniyappa R, Hall G, Kolodziej TL, Karne RJ, Crandon SK, Quon MJ. Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension. Am J Clin Nutr. 2008 Dec;88(6):1685-96. doi: 10.3945/ajcn.2008.26457.</citation>
    <PMID>19064532</PMID>
  </reference>
  <reference>
    <citation>Collins QF, Liu HY, Pi J, Liu Z, Quon MJ, Cao W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem. 2007 Oct 12;282(41):30143-9. Epub 2007 Aug 27.</citation>
    <PMID>17724029</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2009</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stefano Rizza</name_title>
    <organization>Medicine Internal Department</organization>
  </responsible_party>
  <keyword>endothelial</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>hesperidin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

